Table 2 Summary risk estimates of the association between parous and pancreatic cancer.
From: Parity and pancreatic cancer risk: evidence from a meta-analysis of twenty epidemiologic studies
No. of reports | RR (95%CI) | P | I 2 | Ph* | |
|---|---|---|---|---|---|
Overall | 38 | 0.91 (0.85–0.97) | <0.01 | 39.0 | 0.01 |
Subgroup analysis | |||||
Study design | |||||
Cohort | 24 | 0.89 (0.84–0.95) | <0.01 | 28.7 | 0.10 |
Case-control | 14 | 0.95 (0.76–1.18) | 0.62 | 50.6 | 0.02 |
Number of cases | |||||
<100 | 27 | 0.90 (0.81–1.00) | 0.05 | 26.8 | 0.10 |
>100 | 11 | 0.81 (0.84–0.99) | 0.03 | 60.2 | 0.01 |
Location | |||||
Europe | 15 | 0.82 (0.76–0.89) | <0.01 | 16.3 | 0.27 |
North America | 23 | 0.97 (0.89–1.04) | 0.37 | 20.8 | 0.18 |
